MedPath

XprESS Registry Study

Not Applicable
Completed
Conditions
Sinusitis
Interventions
Device: XprESS Balloon Device
Registration Number
NCT01115309
Lead Sponsor
Entellus Medical, Inc.
Brief Summary

This is a prospective, non-randomized, multi-center study to assess safety and long-term patency of the ostia treated with the XprESS device per the device indication for use (IFU).

Detailed Description

Endoscopic balloon-only and hybrid-balloon procedures involving dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia were performed in 175 patients.

One-month follow-up was required for all patients. The first 50 patients enrolled also consented to a 1-year follow-up. Complications and sinus symptom severity were assessed at the 1-month visit. Symptom severity and ostial patency of the treated sinuses were evaluated at the 1-year visit.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
175
Inclusion Criteria
  • 18 years of age or older
  • Scheduled to undergo sinus surgery with planned use of the XprESS Balloon Device consistent with the tool's Indication for Use
  • Willing and able to provide consent
Exclusion Criteria
  • Known Samter's Triad
  • History of primary ciliary dysfunction
  • History of cystic fibrosis
  • Known to be immunosuppressed
  • Hemophilia
  • Currently enrolled in another pre-approval investigational study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
XprESS Balloon DeviceXprESS Balloon DeviceSinus dilation
Primary Outcome Measures
NameTimeMethod
Safety Assessments1 month after procedure

Adverse event reporting as related to XprESS device or procedure

Secondary Outcome Measures
NameTimeMethod
Sino-Nasal Outcome Test (SNOT-20) at 1 MonthBaseline and 1 month after procedure

The 20-item Sino-Nasal Outcome Test (SNOT-20) is a validated, patient-reported outcome assessment to measure the presence and severity of symptoms of chronic rhinosinusitis. Each symptom is scored from 0 (no problem) to 5 (as bad as it can be). The overall score is the mean of the 20 individual items, with a range from 0 to 5 with higher scores indicating greater disease severity. A difference of 0.8 has been determined to be the minimal clinically important difference (MCID) for the SNOT-20.

SNOT-20 at 6 MonthsBaseline and 6 months post procedure

The 20-item Sino-Nasal Outcome Test (SNOT-20) is a validated, patient-reported outcome assessment to measure the presence and severity of symptoms of chronic rhinosinusitis. Each symptom is scored from 0 (no problem) to 5 (as bad as it can be). The overall score is the mean of the 20 individual items, with a range from 0 to 5 with higher scores indicating greater disease severity. A difference of 0.8 has been determined to be the minimal clinically important difference (MCID) for the SNOT-20.

SNOT-20 at 12 MonthsBaseline and 12 months post procedure

The 20-item Sino-Nasal Outcome Test (SNOT-20) is a validated, patient-reported outcome assessment to measure the presence and severity of symptoms of chronic rhinosinusitis. Each symptom is scored from 0 (no problem) to 5 (as bad as it can be). The overall score is the mean of the 20 individual items, with a range from 0 to 5 with higher scores indicating greater disease severity. A difference of 0.8 has been determined to be the minimal clinically important difference (MCID) for the SNOT-20.

Trial Locations

Locations (1)

Texas Sinus Center

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath